Objective: Conventional serologic typing of red blood cell systems other than ABO and RhD can be inaccurate and difficult to interpret in patients who have recently undergone blood transfusion. While molecular-based assays are not used routinely, the usefulness of genotyping was investigated in order to determine patients who may benefit from this procedure. 
Introduction
Patients who require multiple transfusions of red blood cells (RBCs), such as those with sickle cell disease (SCD) or β-thalassaemia, have a higher potential risk of alloimmunisation and delayed haemolytic transfusion reactions (DHTRs). The widely described risk of developing antibodies, mostly to Rh, Kell, Duffy, Kidd, and MNS systems, ranges from 18% to 47% [1, 2] . Programs to prevent alloimmunisation have been implemented in the centres treating patients with SCD and β-thalassaemia [1, 3, 4] . In addition to ABO and RhD matching, protocols range from providing limited antigen-matched RBCs for Rh and Kell to extended antigen-matched RBCs for Rh, Kell, Duffy, Kidd, and MNS systems prior to transfusion.
Accurate phenotyping of multitransfused patients is often complicated, mostly due to the presence of circulating transfused donor RBCs in the recipient's blood, leading to discrepancies in the assessment of tests results. The importance of the genotyping of clinically relevant antigens (such as C, c, E, K, Fy a , Fy b , Jk a , Jk b , and S) in addition to phenotyping is still being discussed for patients with SCD, β-thalassaemia, and other haemoglobinopathies.
However, there is a lack of information about the need for molecular testing for other groups of patients who depend on long-term RBCs transfusions, such as those with myelodysplastic syndrome, myelofibrosis, or chronic renal failure [5, 6, 7] . Delayed haemolytic transfusion reactions are often an issue in these patients, affecting their quality of life and sometimes being fatal. The selection of antigen-negative RBCs in order to reduce alloimmunisation is often required for patients with long-term transfusions and for those with formed alloantibodies.
The most common causes of DHTR include antibodies against Rh, Kell, Kidd, Duffy, and MNS systems [3, 8, 9, 10] . Serological testing and evaluation of the antigens and antibodies of the Duffy and Kidd systems are among the main problems in multitransfused patients. The correlation between serological and molecular typing of Duffy and Kidd systems demonstrates the benefits of genotyping in patients who depend on chronic RBC transfusions.
The aim of our study was to estimate the value of DNAbased typing of Duffy and Kidd systems in chronically transfused non-SCD or β-thalassaemia patients, and to establish the impact of the amount of transfused RBCs and the time from the last transfusion on the discrepancy of the results.
Materials and Methods

Patients
Peripheral blood samples were obtained from 101 patients with haematological and oncological diseases, chronic renal failure, and gastrointestinal diseases. All patients received 3 or more units of RBCs during the last 3 months. The inclusion criteria were the time frame from the last RBC transfusion being shorter than 8 weeks and the need for further Most of the RBC units received by the haematology patients and some of those received by the oncology patients were leucodepleted, while others were non-leucodepleted. Thus, 62 patients (61.4%) were transfused with leucoreduced RBCs, and 39 (38.6%) with entirely (or by more than half) non-leucoreduced RBCs. The median number of transfusion events per patient was 3 (mean: 3.33±0.21, range: 1-12). A median of 2 (mean: 1.85±0.04, range: 1-4) RBC units were administered per transfusion event and 4 (mean: 6.1±0.41, range: 3-24) units per patient.
Donors
In total, 49 blood donors served as controls in our study. Blood samples of donors were obtained by taking 1 or 2 segments of tubes from RBC bags used for transfusions. This control group and the patient group were used to determine frequencies of Duffy and Kidd phenotypes in a Lithuanian population.
Blood samples of all patients and donors were tested for Fy a , Fy b , Jk a , and Jk b antigens by applying serological and molecular methods. Approval for the study was obtained from the Regional Bioethics Committee.
Serotyping Peripheral blood samples were used for Duffy and Kidd phenotyping. Fy a , Fy b , Jk a , and Jk b antigens were determined by haemagglutination using anti-Fy a , anti-Fy b , anti-Jk a , and anti-Jk b Coombs reactive (polyclonal, human) reagents (Antitoxin GmbH, Germany) and DG Gel Coombs cards (Diagnostic Grifols, S.A., Spain). Each microtube of the card contained polymerised dextran in a buffered medium containing preservatives and low ionic strength solution, and was mixed with polyspecific anti-human globulin.
The tests were performed according to the manufacturer's recommendations. The results of the agglutination were expressed by using plus/minus values. Positive results were evaluated from 1+ to 4+.
Genotyping
The DNA was extracted from peripheral blood leucocytes using a DNA extraction kit (GeneJet Genomic DNA Purification Kit, Thermo Fisher Scientific, USA), following the manufacturer's instructions. Polymorphism was identified by polymerase chain reaction-restriction length polymorphism (PCR-RFLP) analysis according to Reid et al. [7] . Briefly, each PCR reaction was carried out in a total volume of 25 µL containing 1X DreamTaq standard buffer, template DNA, 50 pM of each primer, 2.0 mM MgCl 2 , 200 µM of each dNTP, and 1 U of DreamTaq DNA polymerase (Thermo Fisher Scientific) with annealing at 62 °C.
The amplification products were then digested overnight by restriction endonuclease BanI (Thermo Fisher Scientific), following the manufacturer's instructions. The fragments were separated electrophoretically using 2% agarose gel containing ethidium bromide.
The Duffy antigen is present in 2 major allelic forms, FY*A and FY*B, differing in an amino acid at position 42 (Gly42Asp) of the Duffy antigen receptor. The amino acid change occurs because of G125A polymorphism in the Duffy antigen receptor for the chemokine gene (DARC).
The Kidd antigen system is known to comprise 2 major alleles, JK*A and JK*B, which result from a single nucleotide polymorphism (838G→A) in gene SLC14A1. The corresponding JK*A and JK*B antigens differ by a single amino acid (D280N).
Statistical Analysis
The comparison of medians between the groups was performed by applying the nonparametric Mann-Whitney U test. We did not compare the means because the values of the studied variables were not normally distributed (KolmogorovSmirnov test, p<0.05). The 2-proportion z-test, chi-square test, and Fisher's exact test (for small samples) were used for categorical data analysis. The level of agreement between dichotomous results of 2 tests was measured using Cohen's kappa. Differences were considered significant at p<0.05. IBM SPSS Statistics 20 was used for the data analysis.
Results
Donors
Coincidence between phenotype and genotype was observed in all 49 donor samples.
Patients
Disagreements of phenotype and genotype between the Duffy and Kidd systems were found in one-third of the samples of 101 patients who had recently undergone transfusion. The results of phenotyping and genotyping are presented in Table 1 .
To analyse the impact of time from the last transfusion on the discrepancies of the results, patients were distributed Significantly different results were found when comparing the number of RBC units transfused during the last 3 months between the 2 aforementioned groups. A median of 5 (mean: 6.85±0.69) units were transfused during this period to the patients with discrepant phenotype/genotype results versus 4 (mean: 5.71±0.5) to those with accurate results (p=0.025).
Kidd System
Disagreements between genotyping and serologic typing for Jk a /Jk b were found in 32 (31.7%) blood samples, while in samples that did not contain one of the Kidd antigens, discrepant results were found in 65.3% of cases.
Significantly more discrepant phenotype/genotype results were found in the samples of patients of the first group than in those of the second group, at 27 and 5 cases, respectively ( Table 3) .
The time after the last transfusion was shown to be significantly different between the 2 groups of patients. The median of days after the last transfusion was found to be 10. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] ] to those with discrepant results (p=0.188). There was no difference with regard to the number of RBC units transfused during the last 3 months between the 2 aforementioned groups, either. A median of 6 (mean: 6.28±0.48) units were transfused during this period to the patients with discrepant phenotype/genotype results versus a median of 4 (mean: 5.99±0.56) to those with accurate results (p=0.71).
Phenotype Frequencies
Genotyping results were used to determine the expected Duffy and Kidd phenotype frequencies. No differences were found when comparing these results with those of other authors [8, 9] . The phenotypes of 101 patients and 49 controls are presented in Table 4 .
Discussion
It is still disputable which situations require extended typing of transfused RBCs beyond routine matching for ABO, RhD, and existing antibodies. Although a number of studies found that SCD or β-thalassaemia patients may benefit from extended antigen matching, there is still a lack of recommendations in this context for other patients undergoing long-term RBC transfusions [1, 11, 12] .
Additional antibodies are known to occur in 20% to 90% of previously alloimmunised patients [13, 14, 15] . Schonewille et al. evaluated the incidence of new antibody formation with subsequent transfusion in 22% of alloimmunised haematooncology patients and in 20%-25% of the non-haematology/ oncology cohort [14, 15] . The transfusion of extended antigen-matched RBCs, including Duffy and Kidd systems, has been shown to lower alloimmunisation in about 70% of cases [16, 17] . According to these studies as well as those investigating SCD patients, extended antigen matching could be recommended for haemato-oncology patients and other subjects who undergo long-term transfusions.
We agree with the many authors who state that antigen typing of recently transfused patients is not always accurate, as their peripheral blood contains transfused cells [5, 6, 13, 18, 19] . Several reports describe this type of discrepancy in up to 10% of cases for the Duffy and Kidd systems by comparing phenotyping and genotyping results [6, 18, 20] . These findings differ from our data, which showed a much higher rate of discrepancies (32.7% and 31.7%), although the results cannot be accurately compared because other authors failed to provide information about the number of transfused RBC units or the time frame from the last transfusion.
In contrast to a number of previous studies [6, 18, 20, 21, 22] , our data do not suggest the presence of additional Duffy system alleles (which are known to be associated with reduced or abolished gene expression) either in patients or in donors. This is likely due to the fact that only genotypes of the Caucasian population were tested in our study.
The phenotyping/genotyping results in a group of patients who received transfusions within a time period of 7 days before sample collection also differed from those reported earlier, particularly for the Kidd system [5, 7] . In this group, a total of 24 samples in our study showed positive (2+ to 4+) results for Fy a , Fy b , Jk a , and Jk b , although genotypically, 14 of them were Fy a -or Fy b -negative, and 14 were Jk a -or Jk b -negative. Reid et al. described concordant phenotype/genotype results for 7 samples and mixed-field agglutination for 32 samples for Duffy antigens; they also described coincident results for 16 samples and mixed-field agglutination for 31 samples for the Kidd system [7] .
Our data suggest the need for blood group genotyping (including the Duffy and Kidd systems), which was proposed by many authors [1, 2, 3, 4, 5, 6, 7, 11, 13, 16, 18, 19, 20, 23, 24, 25] . Nevertheless, one should determine when genotyping should replace serology or be combined with it for patients undergoing long-lasting RBC transfusions. This is particularly important for institutions that do not perform blood group genotyping routinely. We found in our study that Duffy genotyping/ phenotyping disagreements depended on the number of transfused RBC units during the last 3 months. However, it would be difficult to predict how many units would cause these discrepancies or to make specific recommendations. The limitation of our study is the small number of subjects, which complicated their grouping according to the number of transfused RBC units.
The results of our study regarding the effect of the length of time after the last transfusion on serology findings are useful in clinical practice. A significantly lower number of Duffy and Kidd phenotyping/genotyping discrepancies was found in patients who underwent their last transfusions more than 3 (p=0.01 and p=0.017, respectively) or 4 (p=0.003 and p=0.018, respectively) weeks before the sample collection. Only one disagreement for the Duffy system (compared to 3 for the Kidd system) was found when the time from the last transfusion was from 6 to 7 weeks. No discrepancies were found for either system when the last transfusion was performed more than 7 weeks before.
Our data are also in agreement with previous reports indicating that the range of agglutination in mixed-field reactions does not predict the actual antigen typing [7] . For example, 10 patients in the discrepant group with 2+ reaction for Fy a and 2+ or 3+ reaction for Fy b had FY*B/FY*B genotypes. In the group with accurate results, 7 genotypically FY*A/ FY*B samples also showed 2+ agglutination with anti-Fy a . An exception could be made for serologic reactions with the expression of 1+. All 5 of the 1+ reactions in the Duffy system typing as well as 8 respective reactions in the Kidd typing genetically showed no allele expression. Those reactions were classified as serologically negative. More research is needed to confirm this statement.
Conclusions
Our study showed that Duffy or Kidd phenotyping with agglutination tests is inappropriate for patients who have recently undergone blood transfusion. Genotyping should be considered when the patient underwent transfusion less than 4 weeks before the sample collection. The group of patients who recently (<7 weeks) received RBC transfusion and require genotyping in addition to phenotyping are those who are homozygous for either Duffy or Kidd, but this cannot be ascertained using serology. Agglutination tests can be reliably used for donors and patients who have been transfused more than 7 weeks before.
Furthermore, the accurate typing of both the Kidd and Duffy systems before the first transfusion could be beneficial.
